To examine the cost-effectiveness of moving from usual care to more organized management strategies for patients on chronic warfarin therapy.
W
arfarin is the mainstay of long-term anticoagulation therapy in the United States. Although warfarin therapy reduces disability and fatal thromboembolic events, it can also cause disabling and fatal hemorrhagic events. 1 Therefore, to maximize the efficacy of warfarin, frequent monitoring of the international normalized ratio (INR) of the prothrombin time is required.
The majority of patients receiving chronic warfarin therapy are managed in traditional office settings, but some are managed in formal anticoagulation clinics. 2 Such clinics have been shown to improve the time spent within therapeutic range, as well as to reduce thromboembolic events and hemorrhagic complications. 3, 4 With the 1997 Food and Drug Administration approval of capillary monitors for patient use, it became possible not only to have INR values available immediately, but also for patients to determine their INR without traveling to a clinic or laboratory. The few studies that have evaluated the effectiveness of home testing have found that patients testing at home check their INRs more often and are within the therapeutic range more often than those tested in an anticoagulation clinic. [5] [6] [7] Others have found that patient self-testing decreases adverse events, 8 and is preferred by patients. 9 Despite evidence that the tighter therapeutic control allowed by the introduction of organized anticoagulation clinics and capillary monitors may prevent complications, the introduction of such clinics and devices has been relatively slow, and the cost-effectiveness of the different testing and monitoring alternatives remains unknown. We therefore sought to evaluate the cost-effectiveness of three management alternatives: usual care, anticoagulation clinic testing, and patient self-testing.
METHODS

The Decision Model
An overview of the underlying decision tree is presented in Figure 1 . For modeling purposes, we assumed "usual care" to consist of a venipuncture blood draw for an INR, delayed test results, and no organized anticoagulation clinic. "Anticoagulation clinic testing" consisted of in-clinic capillary monitors for INRs, immediate test results, and an organized anticoagulation clinic. (Organized anticoagulation clinics generally consist of dedicated nursing or pharmacy staff who use explicit protocols and processes to monitor and adjust dosage among patients on warfarin therapy and to seek physician consult). "Patient self-testing" consisted of at-home capillary monitors for INRs with immediate test results managed by patients telephoning these results to an organized anticoagulation clinic.
As illustrated in Figure 1 , for each monitoring alternative, the time patients spend below, in, and above JGIM therapeutic range is estimated and used to derive the associated risk of first and subsequent thromboembolic and hemorrhagic events. Once an event occurs, individuals are at risk of temporary and permanent disabilities. Among individuals who become permanently disabled, there is a risk of discontinuing anticoagulation therapy and thus being at an increased risk of subsequent thromboembolic events.
The decision tree was operationalized as a Markov model in Excel. In the model, hypothetical cohorts of patients are followed for 5 years following warfarin therapy initiation. To parallel the clinical data on thromboembolic and hemorrhagic events available, the model was built to be reflective of patients initiating therapy at age 57 years. 10, 11 With each 1-year cycle of the model, patients move among five defined health states (no prior event; prior event, nondisabled, continuing therapy; prior event, permanently disabled, continuing therapy; prior event, permanently disabled, discontinued therapy; and dead). Transitions among these states were defined using event probabilities drawn from the scientific literature, supplemented with information available within the authors' institution and, when voids remained, expert opinion.
Specifically, four key clinical assumptions were needed: (1) estimates of the time spent below, in, and above therapeutic range for each of the three management alternatives; (2) the risk of incurring an adverse event associated with these times; (3) the risk of disability following an adverse event; and (4) among those permanently disabled, the risk of discontinuing anticoagulation therapy. These clinical assumptions and the corresponding transition probabilities are described below.
For the baseline model, the estimated times spent below and above therapeutic range for usual care reflected those reported by Chiquette et al., 3 Hasenkam et al., 7 Gottlieb and Salem-Schatz, 12 and our own clinical experiences. Using the average of these values, we assumed patients receiving usual care spend 33% of their time (range, 15%-50%) below and 17% of their time (range, 10%-25%) above therapeutic range. For anticoagulation clinic testing, we assumed that patients spend 26% percent of their time (range, 8%-40%) below and 9% of their time (range, 1%-17%) above therapeutic range to reflect the averages of those reported by a number of large anticoagulation clinical trials, [13] [14] [15] [16] [17] [18] [19] [20] [21] as well as data from four observational studies. 3, 6, 22, 23 For patient self-testing, patients were assumed to spend 6% of their time (range, 5%-15%) below and 5% of their time (range, 1%-7%) above therapeutic range, reflecting the average of those reported by White et al., 23 Anderson et al., 9 Ansell et al., 6 and Hasenkam et al. 7 Associated with these estimates of time spent below, in, and above therapeutic range are first and subsequent thromboembolic and hemorrhagic event rates (Table 1) . Transition probabilities for event rates were derived from a longitudinal study of patients seen in five anticoagulation clinics. 5, 10, 11 Published data from this study were supplemented with unpublished data provided by Dr. Stephan Fihn and colleagues. The average age of this population was 57 years and 81% were male. Thirty percent had a primary indication of deep vein thrombosis or pulmonary embolism, while 26% and 14% were on warfarin for valvular disease and atrial fibrillation, respectively. Finally, 21% had experienced a cerebral or systemic embolism, 7% had other circulatory conditions, and the remaining 3% were on warfarin for other conditions. 10 Although the study by Fihn et al. was done before INR reporting was commonplace: however, the classification system for prothrombin time therapeutic range used in their study afforded the ability to translate into INRdefined therapeutic ranges. 10 To do so, we assumed an international sensitivity index (ISI) of 2.3. 10 As proposed by Fihn et al., events were classified into three categories requiring medical care: serious, life-threatening, or fatal. 10, 11 Serious events include bleeding that requires endoscopy, recurrent deep vein thrombosis, and transient ischemic attack. Life-threatening events are those that require urgent treatment or cause irreversible sequelae; examples include myocardial infarction, stroke, and bleeding leading to surgery.
We assumed that 60% of all life-threatening thromboembolic events [24] [25] [26] [27] [28] and 10% of all life-threatening hemorrhagic events 5 resulted in permanent disability. Among some patients incurring a disabling event, the risk associated with continued warfarin use most likely outweighs the potential benefits. Our model therefore allowed for a proportion of those who were permanently disabled to discontinue warfarin therapy. To our knowledge, no published data are available on the percentage of individuals who discontinue therapy after becoming permanently disabled. As a baseline, we assumed that 50% would do so after a permanently disabling event. Among individuals who discontinued therapy, the risks of a subsequent thromboembolic event (17%) and hemorrhagic event (1%) were derived from those reported for members of the control group of a large randomized anticoagulation trial for secondary prevention. 15 Using data from several studies that have assigned utilities to the adverse events associated with anticoagulation therapy, [29] [30] [31] [32] [33] we also estimated the quality-adjusted life years (QALYs) expected with each management alternative. For patients who suffered a temporarily disabling event, a utility of 0.75 was assigned for the 30 days following the event. For individuals who suffered a permanently disabling event, a utility of 0.50 was assigned from the time of the event until death or the end of the 5-year modeling period, whichever came first. Because the validity and reliability of these reported QALYs is untested, we elected to vary these estimates over a wide range in the sensitivity analyses.
For each of these assumptions, we conducted sensitivity analyses to determine the robustness of model results to underlying assumptions. One-way sensitivity analysis was conducted for assumptions of particular interest, and multiple-way sensitivity analysis was conducted using Crystal Ball, 34 a program that enables Monte Carlo analysis. The more uncertain the data on which we based an assumption, the wider the range we tested around the assumption in the sensitivity analyses.
All data were compiled and all analyses and interpretations were conducted by the authors, independent of Roche Diagnostic (formerly Boehringer Mannheim) staff, the funding source for the study. The two exceptions to this were data on the base model device cost and estimated 
Cost Data
The direct medical care costs of anticoagulation monitoring and of thromboembolic and hemorrhagic events are used to estimate the model. These costs were drawn from the scientific literature, supplemented with information available within the authors' institution and, when needed, expert opinion. To approximate the reference case as recommended by the Panel on Cost-Effectiveness in Health and Medicine, 35 we included the costs associated with anticoagulation testing, monitoring, and adverse events (including nursing home costs), as well as the costs incurred by patients and their caregivers in receiving care. Model results are presented from two perspectives: a medical provider perspective, which includes all direct medical care costs, including nursing home costs; and a societal perspective, which includes the costs incurred by medical providers, and by patients and their caregivers in receipt of care. All costs and health outcomes were discounted at a base rate of 3%, 35 and all monetary amounts reflect 1997 dollars.
As shown in Table 2 , annual anticoagulation management costs were derived using an estimated testing frequency of 14 times per year for usual care, 12 23 times per year for anticoagulation clinic testing, 6 and 52 times per year for patient self-testing. 8 The frequencies for usual care and anticoagulation clinic testing are consistent with experiences within our own institution; all reflect the average testing frequency for patient populations that include those who spend time both within and outside the therapeutic range. Included in the direct medical care costs of anticoagulation management were the costs of equipment, supplies, and staff time (i.e., nurse and physician time). Although we assumed the average physician time per consult to be consistent across the three management alternatives (i.e., 2 minutes), 36 we assumed the frequency with which the physician is consulted to be reduced once an anticoagulation clinic had been established (i.e., 90% vs. 10%). 36 Nursing time per test was assumed to be 13 minutes for usual care, 15 minutes for anticoagulation clinic testing, and 8 minutes for patient self-testing. Valuation of these resources was achieved by using prevailing wage and price data from our institution and therefore reflects the acquisition cost to a provider organization. Also reflective of the acquisition cost to a provider organization was the price used in the base model for the capillary monitor-$1,385.
Included in the costs of anticoagulation management faced by patients and their caregivers were time and travel costs ( Table 2) . Time costs, which include travel, waiting, training, and testing times, were estimated to be 17 minutes for usual care, 20 minutes for anticoagulation clinic testing, and 15 minutes for self-testing. 36 They were valued using prevailing national wage rates for individuals aged 55 to 64 years ($14.10 per hour). 37 From experiences in our anticoagulation clinic, we assumed 30% of patients were accompanied by a family member for clinicbased testing. Nine percent were assumed to receive help with home testing. 38 So as to estimate only the marginal costs associated with INR testing, no travel costs were associated with any testing assumed to occur during routine visits. (In the base model, we assumed seven such visits per year.) Table 3 presents the average cost for adverse events used in the model. Included in these were office visit, emergency department, and hospital admission costs. The underlying resource use (e.g., length of stay) from which these estimates were derived was from the stroke-related literature, 39, 40 as well as a sample of 50 patients receiving anticoagulation therapy from our institution. Valuation of these resources was achieved by using our institution's cost estimates and published data. 41 For individuals who were institutionalized, the cost of nursing home care was also included. Table 4 presents the number of adverse events by severity expected with each of the three management strategies. As illustrated in Table 4 , 3.7 events per 100 patients could be avoided by moving from usual care to anticoagulation clinic testing, and another 4.9 events per 100 patients could be avoided by moving from anticoagulation clinic testing to patient self-testing over a 5-year period.
RESULTS
Baseline Analysis
Because the majority of these events are not fatal, the expected differences in life years among the three alternatives are relatively small (i.e., Ͻ 0.2). However, as many life-threatening and serious events result in disability, moving from usual care to anticoagulation clinic testing would result in an increase of 0.5 QALY per 100 patients, and moving from anticoagulation clinic testing to patient self-testing would result in an additional 0.8 QALY per 100 patients over the 5-year period. Table 5 presents the discounted 5-year costs associated with each of the three management alternatives. Although the increased frequency of testing that occurs with anticoagulation clinic testing (23 vs 14) drives up the costs of testing compared with those incurred in usual care, these cost increases are more than offset with the savings due to avoided adverse events and their sequelae, making anticoagulation clinic testing a financially appealing alternative to usual care in terms of associated medical care costs. On the other hand, moving from anticoagulation clinic testing to patient self-testing is expected to result in an overall increase in medical care costs, as the savings due to reduced adverse events are not completely offset by the increased costs of testing.
In addition to the direct medical care costs, we considered the costs incurred by patients and their caregivers in receiving care. Because of the increased frequency of testing (and the associated time and travel costs), an increase of almost $130,000 per 100 patients is realized in the costs incurred by patients and their caregivers when moving from usual care to anticoagulation clinic testing. On the other hand, because of the reduction in time and travel costs associated with patient self-testing, even with a substantial increase in the frequency of testing, an overall cost saving of over $140,000 per 100 patients would be realized when moving from anticoagulation clinic testing to patient self-testing.
The net result is that the discounted incremental cost-effectiveness ratios differ substantially depending on whether or not the costs incurred by patients and their caregivers are included. As illustrated in Table 6 , when these costs are considered ("All Costs"), moving from usual care to anticoagulation clinic testing results in a cost-effectiveness ratio of $31,327 per avoided event (or $232,226 per QALY), and moving from anticoagulation clinic testing to patient self-testing results in an expected cost saving. However, when patient and caregiver costs are ignored, moving from usual care to anticoagulation clinic testing results in a cost saving, while moving from anticoagulation clinic testing to patient self-testing results in a cost-effectiveness ratio of $24,818 per avoided event (or $153,504 per QALY).
Sensitivity Analyses
We conducted one-way sensitivity analyses for model assumptions including time spent outside therapeutic range, disability rates, the resource use associated with adverse events, the proportion of the disabled population that discontinued therapy, the resources required for anticoagulation management, the wage rate used to value patient and caregiver time, and the discount rate. In general, model findings of overall cost increases or savings were most sensitive to assumptions regarding time spent below and above therapeutic range. For example, a relatively small change in the time spent below and above therapeutic range (i.e., 4%-6%) led to a cost increase instead of a savings in medical care costs when moving from usual care to anticoagulation clinic testing. In addition, the model findings of cost increases or savings are sensitive to annual testing frequency. For example, if frequency of testing for patient self-testing increases to 57 times a year (base 52), then moving from anticoagulation testing to patient self-testing would no longer be cost saving when all costs are included, although the cost would still be a modest $608 per event avoided or $3,758 per QALY. Converseley, overall model results were not sensitive to the discount rate used (range, 0%-10%), or assumptions regarding the percentage of patients discontinuing therapy after a permanent disability (range, 20%-80%), the wage rate used to value patient and caregiver time (range, $11-$17 per hour), and the annual number of tests that would occur during routine visits (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . A multi-way sensitivity analysis, in which all assumptions within the model were allowed to vary within their specified ranges, confirmed overall results. Moving from usual care to anticoagulation clinic testing is likely to result in a reduction in the number of events (88% certainty), an increase in life years (79% certainty), and a decrease in disabled life years (80% certainty). Similarly, moving from anticoagulation clinic testing to patient selftesting will also result in a reduction in the number of events (91% certainty), an increase in life years (85% certainty), and a decrease in disabled life years (95% certainty). In addition, when only medical care costs are considered, results indicate that moving from usual care to anticoagulation clinic testing is likely to be cost saving (80% certainty), and when patient and caregiver costs incurred are included, moving from anticoagulation clinic testing to patient self-testing may result in a cost saving (48% certainty).
DISCUSSION
Consistent evidence exists that the more time a patient spends within his or her therapeutic range, the fewer events he or she has. The practical issues of how to manage patients most appropriately to keep them within therapeutic range, however, remain unclear. The establishment of anticoagulation clinics seems to be the current best answer, and a randomized trial evaluating their effectiveness is currently underway. 2 Incorporating newer technologies, like capillary monitors, into the management process may further improve patient outcomes. This model addresses both the health and economic implications of more organized management of patients receiving chronic warfarin therapy: anticoagulation clinic testing and patient self-testing.
Model results illustrate the potential health benefits of such a move: over a 5-year period, moving from usual care to anticoagulation clinic testing would reduce the number of adverse events per 100 patients by 3.7, and moving from anticoagulation clinic testing to patient selftesting would result in a reduction of another 4.9 events.
The model also illustrates the importance of considering fully the economic impact to each of the different entities involved. From a medical care provider perspective, this model demonstrates that an anticoagulation clinic testing approach would provide a cost-effective, in fact a cost-saving, alternative to usual care. However, the burden that such an approach would place on patients and their caregivers cannot be ignored. The increased frequency of testing associated with anticoagulation clinic testing relative to usual care substantially increases the time-and travel-related costs to patients and their caregivers. Once these costs are included, patient self-testing becomes the most cost-effective alternative to usual care.
Two potential limitations of the model warrant reiteration. First, the adverse event rates used were based on a population that included relatively few patients with atrial fibrillation. Ideally, we would have based estimates of event rates on data derived from a population more reflective of those currently receiving warfarin therapy, that is, one with a larger percentage of patients with atrial fibrillation. However, we know of no database that includes thromboembolic and hemorrhagic event rates by either management alternative or time within therapeutic range for such a population. Second, although we are conducting a randomized clinical trial comparing time spent within and outside therapeutic range by different management alternatives, to date no such trial data exist. Therefore, we were forced to rely on observational data for modeling assumptions regarding time spent below, in, and above therapeutic range. Although model findings of cost savings are sensitive to these assumptions, the relative ranking of the alternatives generally is not. That is, almost without exception, anticoagulation clinic testing is the most cost-effective alternative to usual care when costs to patients and their caregivers are ignored, and once these costs are included, patient self-testing becomes the most clinically effective and cost-effective alternative. 
